Journal
NATURE REVIEWS IMMUNOLOGY
Volume 10, Issue 8, Pages 554-567Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nri2808
Keywords
-
Categories
Funding
- Cancer Research Institute
- NCI [P50 CA121974]
- PEW Charitable Trust
- NIH [CA121974, DK051665]
- JDRF [32-2008-352]
Ask authors/readers for more resources
Transforming growth factor-beta (TGF beta) is an immunosuppressive cytokine produced by tumour cells and immune cells that can polarize many components of the immune system. This Review covers the effects of TGF beta on natural killer (NK) cells, dendritic cells, macrophages, neutrophils, CD8(+) and CD4(+) effector and regulatory T cells, and NKT cells in animal tumour models and in patients with cancer. Collectively, many recent studies favour the hypothesis that blocking TGF beta-induced signalling in the tumour microenvironment enhances antitumour immunity and may be beneficial for cancer therapy. An overview of the current drugs and reagents available for inhibiting TGF beta-induced signalling and their phase in clinical development is also provided.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available